Patent 9487764 was granted and assigned to Synlogic on November, 2016 by the United States Patent and Trademark Office.
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.